For the quarter ending 2025-09-30, APVO had $11,651K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,549 | -12,612 |
| Stock-based compensation | 77 | 17 |
| Depreciation and amortization | 49 | 110 |
| Prepaid expenses and other current assets | -83 | -274 |
| Operating lease right-of-use asset | 148 | 278 |
| Accounts payable, accrued compensation and other liabilities | 724 | -1,315 |
| Long-term operating lease liability | -220 | -420 |
| Net cash used in operating activities | -6,688 | -13,668 |
| Proceeds from issuance of common stock and pre-funded warrants exercise, net of issuance costs | - | 14,364 |
| Proceeds from issuance of common stock, pre-funded warrants exercise, and common warrants exercise, net of issuance costs | 32,703 | - |
| Net cash used in financing activities | 18,339 | 14,364 |
| Increase (decrease) in cash and cash equivalents | 11,651 | 696 |
| Cash and cash equivalents at beginning of period | 8,714 | - |
| Cash and cash equivalents at end of period | 21,061 | - |
Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc. (APVO)